Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 11,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Hereditary Eye Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 6 Months and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib granule formulation, Selumetinib capsule formulation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more

Conditions: Twin Monochorionic Diamniotic Placenta
Interventions: Fetoscopy Sets for Anterior and Posterior Placentas; Device
Lead sponsor: Michael A Belfort; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dermatitis, Atopic
Interventions: BMS-986166, Branebrutinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Fremont, California • Brandon, Florida • Coral Gables, Florida + 14 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Not listed
Lead sponsor: Biocerna LLC; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fulton, Maryland

Conditions: Rett Syndrome, RTT, Rett Syndrome, Atypical
Interventions: EEG and Auditory and Visual Evoked Potentials (AEP and VEP), Clinical assessment; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 18 Years · Female only
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Brookline, Massachusetts + 3 more

Conditions: Polycystic Ovary Syndrome
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Springfield, Missouri • Philadelphia, Pennsylvania

Conditions: X-Linked Hypophosphatemia
Interventions: Burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 1 Year to 4 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Indianapolis, Indiana • St Louis, Missouri

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution); Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 99
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more

Conditions: Spinocerebellar Ataxia Type I
Interventions: Lithium Carbonate; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fetal Alcohol Spectrum Disorders
Interventions: FMF Connect, Coaching; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cardiac Transplant, Patent Ductus Arterious, Atrial Septal Defect, Bidirectional Cavopulmonary Anastomosis
Interventions: Dexmedetomidine; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: Up to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Anemia
Interventions: Blood smear education, standard education; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Immune Deficiency Disorder, Common Variable Immunodeficiency, Specific Antibody Deficiency, Hypergammaglobulinemia
Interventions: Exercise Program; Other
Lead sponsor: Stockton University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Galloway, New Jersey

Conditions: Down Syndrome, Fetal Aneuploidy
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 6 more

Conditions: Atopic Dermatitis
Interventions: tapinarof cream, 1%, Vehicle cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 53 more

Conditions: Phenylketonuria
Interventions: Sapropterin dihydrochloride; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 9 Years and older
U.S. locations: 36
States / cities: Los Angeles, California • Orange, California • San Diego, California + 33 more

Conditions: Atopic Dermatitis
Interventions: lebrikizumab; Drug
Lead sponsor: Johann E Gudjonsson MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Folsom, California • Ann Arbor, Michigan

Conditions: Hemophilia A, Hemophilia B
Interventions: Virtual Reality Distraction, Standard of Care Distraction; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 19 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions: mycobacteriophage; Biological
Lead sponsor: National Jewish Health; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Dupilumab Prefilled Syringe; Biological
Lead sponsor: Jonathan A. Bernstein, MD; Other
Eligibility: 19 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Herpes Simplex Virus, Neonatal Sepsis
Interventions: Acyclovir; Drug
Lead sponsor: Phillip Brian Smith; Other
Eligibility: Up to 45 Days
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Wichita, Kansas • New Orleans, Louisiana • Durham, North Carolina

Search by objective public record fields.

Evaluation and Treatment of Patients With Inherited Eye Diseases

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

Neurophysiologic Biomarkers in Rett Syndrome

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

Lithium Treatment for Patients With Spinocerebellar Ataxia Type I

Efficacy Trial of the FMF Connect Mobile Health Intervention

The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease

Adherence to Hydroxyurea in Children With Sickle Cell Anemia

The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease

Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Sapropterin Expanded Access Program

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Virtual Reality for Hemophilia

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)